Ketamine for Treatment Resistant Depression

Ketamine for Treatment Resistant Depression
Author: Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke
Publsiher: Academic Press
Total Pages: 168
Release: 2020-10-01
ISBN 10: 0128210346
ISBN 13: 9780128210345
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Book Review:

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Ketamine for Treatment Resistant Depression

Ketamine for Treatment Resistant Depression
Author: Sanjay J. Mathew,Carlos A. Zarate, Jr.
Publsiher: Springer
Total Pages: 155
Release: 2016-11-25
ISBN 10: 3319429256
ISBN 13: 9783319429250
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Book Review:

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Ketamine for Treatment Resistant Depression

Ketamine for Treatment Resistant Depression
Author: Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke
Publsiher: Academic Press
Total Pages: 150
Release: 2020-10-15
ISBN 10: 0128210338
ISBN 13: 9780128210338
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Book Review:

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Rapid Acting Antidepressants

Rapid Acting Antidepressants
Author: Anonim
Publsiher: Academic Press
Total Pages: 402
Release: 2020-06-29
ISBN 10: 0128201908
ISBN 13: 9780128201909
Language: EN, FR, DE, ES & NL

Rapid Acting Antidepressants Book Review:

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series

Ketamine for Depression

Ketamine for Depression
Author: Dr. Stephen J. Hyde
Publsiher: Xlibris Corporation
Total Pages: 222
Release: 2015-09-04
ISBN 10: 1503509532
ISBN 13: 9781503509535
Language: EN, FR, DE, ES & NL

Ketamine for Depression Book Review:

Given the unacceptably high rates of suffering, disability and premature death experienced by people with treatment-resistant depression and the surprisingly low rates of problems arising from the use of ketamine to treat the disorder, this is a therapy that all patients and their doctors should be discussing. This book summarises the research that has been carried out into ketamine for the treatment of depression over the past 15 years and, most importantly, describes different ways of using ketamine that are both practical and cost–effective. Currently most ketamine therapy is given intravenously in specialised clinics at considerable expense, but the author has successfully treated patients with low-dose sublingual ketamine and his patients have been able to safely take this at home. Profits from the sales of this book will assist further research into the use of ketamine for the treatment of depression.

ECDEU assessment manual for psychopharmacology

ECDEU assessment manual for psychopharmacology
Author: William Guy
Publsiher: Unknown
Total Pages: 603
Release: 1976
ISBN 10: 1928374650XXX
ISBN 13: UCR:31210000126621
Language: EN, FR, DE, ES & NL

ECDEU assessment manual for psychopharmacology Book Review:

11 THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT RESISTANT DEPRESSION

11   THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT RESISTANT DEPRESSION
Author: Mariane Quieroti Rodrigues
Publsiher: Unknown
Total Pages: 135
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1163811374
Language: EN, FR, DE, ES & NL

11 THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT RESISTANT DEPRESSION Book Review:

Introduction: Major depressive disorder is highly common with up to 50% to 60% of the patients not achieving adequate response following antidepressant treatment. In this scenario, ketamine emerges as an important alternative to conventional treatments, with its action of being an antagonist of N-methyl- D-aspartate (NMDA) receptor, once its has a quick and effective action. Ketamine is most frequently administered intravenous. However, oral, sublingual, transmucosal, intranasal, subcutaneous (SC), and intramuscular routes of administration have also been examined.Aim: This study aims to investigate whether SC ketamine is effective in the treatment of unipolar major depression and if it has more effective and sustainable response than electroconvulsivetherapy (ECT).Methods: Participants will be comprised of patients with unipolar depression resistant to conventional treatment, men and women, aged u2265 18 across a range of ethnicities, recruited from General Hospital Servidor of State of Su00e3o Paulo, Brazil. Participants will be separeted in two groups. The first one will recieve a SC administration of ketamine in the dose of 0,5mg/kg weekly, for 6 weeks. The second will be submitted to ECT treatment, two sessions a week, for at least 8 sessions. The response of each treatment will be evaluated and compared by MADRS questionnaire.Results: We expect that SC ketamine has a good response in the treatment of major depression and that it has a similar response compared to ECT.Conclusion: SC ketamine, once it is a secure, quick and simple procedure, is a promising alternative to the available treatments.

Treatment resistant Mood Disorders

Treatment resistant Mood Disorders
Author: Andre Carvalho,Roger McIntyre
Publsiher: Oxford University Press, USA
Total Pages: 160
Release: 2014-05-01
ISBN 10: 0198707991
ISBN 13: 9780198707998
Language: EN, FR, DE, ES & NL

Treatment resistant Mood Disorders Book Review:

Treatment-resistant major depression and bipolar disorder are highly prevalent and disabling conditions associated with substantial morbidity and mortality. The assessment and management of refractory patients with mood disorders is a major clinical challenge for mental health providers. Part of the Oxford Psychiatry Library (OPL) series, this pocketbook provides a concise view of the current definitions, assessment and evidence-based management of treatment-resistant mood disorders and reviews novel therapeutic targets for mood disorders, which may enhance the therapeutic armamentarium of clinicians in the near future. The pocketbook serves as a useful guide for mental health practitioners, including psychiatrists, clinical psychologists, trainees, and interested primary care physicians.

Ketamine for Treatment Resistant Depression Or Post Traumatic Stress Disorder in Various Settings

Ketamine for Treatment Resistant Depression Or Post Traumatic Stress Disorder in Various Settings
Author: Joanne Kim
Publsiher: Unknown
Total Pages: 30
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1000218458
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Or Post Traumatic Stress Disorder in Various Settings Book Review:

Depression From Psychopathology to Pharmacotherapy

Depression  From Psychopathology to Pharmacotherapy
Author: J.F. Cryan,B.E. Leonard
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 282
Release: 2010-11-17
ISBN 10: 3805596065
ISBN 13: 9783805596060
Language: EN, FR, DE, ES & NL

Depression From Psychopathology to Pharmacotherapy Book Review:

Despite the availability of antidepressants for over 40 years, a substantial proportion of depressed patients do not respond adequately to treatment. Failure to respond effectively to treatment contributes to physical ill-health and psychiatric morbidity, often resulting in premature death of the depressed patient. The purpose of this volume is to consider the possible reasons for the limitations of the currently available antidepressants, to examine the advances in our understanding of the psychopathology of depression and how such knowledge may assist in the discovery of new methods of treatment. Leading international experts in this field discuss the possible underlying reasons for depression and limitations of current antidepressants. Opportunities for novel therapeutic approaches to dysfunctional circadian rhythms and mood disorders as well as current status and future perspectives for optimizing antidepressant management of depression are reviewed. This publication illustrates the breadth of the latest research and is valuable reading for psychiatrists, neuroscientists and pharmacologists.

Psychopharmacology of Depression

Psychopharmacology of Depression
Author: S. A. Montgomery,Timothy H. Corn
Publsiher: Unknown
Total Pages: 260
Release: 1994
ISBN 10: 1928374650XXX
ISBN 13: UOM:39015032961693
Language: EN, FR, DE, ES & NL

Psychopharmacology of Depression Book Review:

Depression is a common illness with a recurrent and chronic nature. It is not an easy illness to treat because those who suffer from it frequently do not come forward for treatment. Antidepressant drugs have been improved and progress continues, but there are still many aspects of the disease which are poorly understood. This volume discusses a number of novel theories of depression, which partly derive from the advances in the discrimination of receptor subtypes, indicating that the spectrum of depression is far wider and more complex than has been thought. This volume concentrates on the newer mechanisms being explored as potential antidepressants and on the biochemical theories that have produced new treatment approaches.

Ketamine for Treatment Resistant Depression

Ketamine for Treatment Resistant Depression
Author: Sanjay J. Mathew,Carlos A. Zarate, Jr.
Publsiher: Adis
Total Pages: 155
Release: 2018-07-07
ISBN 10: 9783319826950
ISBN 13: 3319826956
Language: EN, FR, DE, ES & NL

Ketamine for Treatment Resistant Depression Book Review:

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

The Valedictorian of Being Dead

The Valedictorian of Being Dead
Author: Heather B. Armstrong
Publsiher: Simon and Schuster
Total Pages: 272
Release: 2019-04-23
ISBN 10: 1501197061
ISBN 13: 9781501197062
Language: EN, FR, DE, ES & NL

The Valedictorian of Being Dead Book Review:

From New York Times bestselling author and blogger Heather B. Armstrong comes an honest and irreverent memoir—reminiscent of the New York Times bestseller Brain on Fire—about her experience as the third person ever to participate in an experimental treatment for depression involving ten rounds of a chemically induced coma approximating brain death. For years, Heather B. Armstrong has alluded to her struggle with depression on her website, dooce. It’s scattered throughout her archive, where it weaves its way through posts about pop culture, music, and motherhood. In 2016, Heather found herself in the depths of a depression she just couldn’t shake, an episode darker and longer than anything she had previously experienced. She had never felt so discouraged by the thought of waking up in the morning, and it threatened to destroy her life. For the sake of herself and her family, Heather decided to risk it all by participating in an experimental clinical trial. Now, for the first time, Heather recalls the torturous eighteen months of suicidal depression she endured and the month-long experimental study in which doctors used propofol anesthesia to quiet all brain activity for a full fifteen minutes before bringing her back from a flatline. Ten times. The experience wasn’t easy. Not for Heather or her family. But a switch was flipped, and Heather hasn’t experienced a single moment of suicidal depression since. “Breathtakingly honest” (Lisa Genova, New York Times bestselling author), self-deprecating, and scientifically fascinating, The Valedictorian of Being Dead brings to light a groundbreaking new treatment for depression. The Valedictorian of Being Dead was previously published with the subtitle “The True Story of Dying Ten Times to Live.”

Antidepressants

Antidepressants
Author: Olivier Berend
Publsiher: BoD – Books on Demand
Total Pages: 124
Release: 2019-11-20
ISBN 10: 1789852668
ISBN 13: 9781789852660
Language: EN, FR, DE, ES & NL

Antidepressants Book Review:

Major depression is a severe and prevalent brain disorder with a high disability burden, hence the push for effective treatments. Antidepressants have been around since the 1950s, and although current medications are much more effective than early ones, there is still much room for improvement. "Real" antidepressants, defined as those that "repair" or "improve" the depression-causing mechanism in the brains of depressed patients, have yet to be identified. This book presents current research on depression and antidepressants, including use of antidepressants in alcohol use disorders and pregnancy, treatment-resistant depression, and development of potential new medications.

Ketamine

Ketamine
Author: Kenji Hashimoto,Soichiro Ide,Kazutaka Ikeda
Publsiher: Springer Nature
Total Pages: 189
Release: 2020-03-05
ISBN 10: 9811529027
ISBN 13: 9789811529023
Language: EN, FR, DE, ES & NL

Ketamine Book Review:

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.

Treating Resistant Depression

Treating Resistant Depression
Author: Joseph Zohar,Robert H. Belmaker
Publsiher: Spectrum Publications
Total Pages: 427
Release: 1987
ISBN 10: 1928374650XXX
ISBN 13: UOM:39015011756866
Language: EN, FR, DE, ES & NL

Treating Resistant Depression Book Review:

Natural Medications for Psychiatric Disorders

Natural Medications for Psychiatric Disorders
Author: David Mischoulon,Jerrold F. Rosenbaum
Publsiher: Lippincott Williams & Wilkins
Total Pages: 366
Release: 2008
ISBN 10: 9780781767620
ISBN 13: 0781767628
Language: EN, FR, DE, ES & NL

Natural Medications for Psychiatric Disorders Book Review:

Updated for its Second Edition, this book is the only reference to focus exclusively on natural medications in psychiatry. Eminent psychiatrists from the Massachusetts General Hospital and other leading institutions examine current scientific and clinical data on the applications, effectiveness, and safety of natural psychotropics and acupuncture. Quick-reference tabular appendices list indications, contraindications, dosages, combinations, and drug-drug interactions for each remedy. This edition includes brand-new chapters on acupuncture, homeopathy, and therapies for substance dependence and weight management. The chapter on polypharmacy and side effect management addresses the growing issue of drug-drug interactions. New introductory chapters discuss complementary and alternative medicine in society and examine research limitations and quality assurance issues.

Treatment Resistant Depression

Treatment Resistant Depression
Author: John F. Greden,Michelle B. Riba,Melvin G. McInnis
Publsiher: American Psychiatric Pub
Total Pages: 338
Release: 2011
ISBN 10: 1585624098
ISBN 13: 9781585624096
Language: EN, FR, DE, ES & NL

Treatment Resistant Depression Book Review:

This unique book presents the treatment "roadmap" implemented by the University of Michigan Comprehensive Depression Center's Treatment Resistant Depression Program, step-by-step guidance that has long eluded clinicians, patients, and their families. Writing across discipline, modality, lifespan, and patient demographics, the authors have compiled the most current thinking on TRD and distilled it into a highly readable, imminently practical, and brilliantly organized source of hope. The authors believe that early intervention is critical, and they advocate strategies for renewed focus on identifying youths who are at risk or already symptomatic. Similarly, they devote chapters to special populations such as pregnant women, older people, and those with comorbidities. Perhaps most useful to patients and their families, the book has a strong self-care orientation, emphasizing the importance of exercise, nutrition, and healthy sleep guidelines. Patients who are actively engaged in managing their disease often have better outcomes. Treatment Resistant Depression is frequently a lifetime diagnosis. The book acknowledges that fact and offers a systematic course of treatment grounded in evidence-based research that is current and comprehensive. Treatment Resistant Depression: A Roadmap for Effective Care offers a new way of conceptualizing an old enemy, and should prove to be an indispensable weapon in the battle.

Treatment resistant Depression Trd

Treatment resistant Depression Trd
Author: Deborah Diaz
Publsiher: Unknown
Total Pages: 100
Release: 2017-02-01
ISBN 10: 9781536108255
ISBN 13: 1536108251
Language: EN, FR, DE, ES & NL

Treatment resistant Depression Trd Book Review:

Major Depressive Disorder (MDD) is a common and debilitating neuropsychiatric disorder with high economic and societal impact. Approximately 30% of subjects with MDD achieve full remission after treatment with conventional antidepressants resulting in a relevant percentage of patients suffering from treatment resistant depression (TRD). Treating TRD is a difficult challenge for psychiatrists due to the complexity of this disabling condition. In fact, TRD is generally associated with a poorer outcome, higher suicidal risk, more severe psychosocial impairment and physical disability when compared to MDD. This book provides new research on treatment options, challenges and the future directions for individuals with TRD.

Ready Set Action Potential Breakthrough Therapy for Treatment Resistant Depression

Ready  Set  Action  Potential Breakthrough Therapy for Treatment Resistant Depression
Author: Alvin Garlejo
Publsiher: Unknown
Total Pages: 135
Release: 2017
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1032006989
Language: EN, FR, DE, ES & NL

Ready Set Action Potential Breakthrough Therapy for Treatment Resistant Depression Book Review:

Major depressive disorder is a psychiatric illness that is associated with a variety of debilitating symptoms such as persistent sadness, lack of interest and motivation, lassitude, pessimistic thoughts, and in severe cases, suicidal ideation and behavior. Current psychological and pharmacological treatments have been demonstrated efficacious; however, an ever-growing number of individuals frequently report minimal to no improvement with these treatments; and in some cases, a worsening of symptoms. This inadequacy to treatment is commonly known as treatment-resistant depression. At Kadima Neuropsychiatry Institute, Dr. Feifel treats individuals with treatment-resistant depression with advanced treatments such as TMS and ketamine. During my fieldwork internship at Kadima Neuropsychiatry Institute, my project focused on evaluating the efficacy of ketamine administered intramuscular to patients with treatment-resistant depression and determining which characteristics of a patient0́9s psychedelic experience or 0́−trip0́+ is associated with the decrease in their depressive symptoms. The results of this project demonstrated that an initial low dose of ketamine was significantly quick and efficacious in decreasing depressive symptoms in patients with treatment resistant depressive. In addition, a first of its kind exploratory analysis suggested that the intensity, positive content, and dissociative characteristics of a ketamine induced psychedelic trip were strongly associated with the decrease in depressive symptoms. Despite the significance in these results, more research needs to include a larger sample and explore the specific subjective characteristics within a psychedelic 0́−trip0́+ to further understand its association with a decrease in depressive symptoms. The quick and efficacious antidepressant effects of ketamine demonstrated in this project provide much potential for a program involving a mobile ketamine clinic to address severe depression and suicidality. Such therapeutic and intervention potentials can be explored further given an expansion of current policy limiting ketamine as a schedule III substance.